Substrate specificity of prostate-specific antigen (PSA)

Chemistry and Biology

Volumn 5, Issue 9, 1998, Pages 475-488

  Coombs, Gary S ^a   Bergstrom, Robert C ^b   Pellequer, Jean Luc ^c   Baker, Scott I ^b   Navre, Marc ^d   Smith, Matthew M ^d   Tainer, John A ^c   Madison, Edwin L ^a   Corey, David R ^b  

^a Dendreon   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d AFFYMAX RESEARCH INSTITUTE   (United States)

Author keywords

Prostate specific antigen; Protease specificity; Subsite occupancy; Substrate phage display

Indexed keywords

AMINO ACID SEQUENCE; ANTIGEN SPECIFICITY; BINDING SITE; CHYMOTRYPSIN; ENZYME INHIBITOR; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; KALLIKREIN; MOLECULAR MODEL; PHAGE DISPLAY; PROSTATE SPECIFIC ANTIGEN; SEMENOGELIN; TRYPSIN;

EID: 0032170483     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(98)90004-7     Document Type: Article

References (60)

1. Seregni, E., Botti, C., Ballabio, G. & Bombardieri, E. (1996). Biochemical characteristics and recent biological knowledge of prostate-specific antigen. Tumori 82, 72-77.
2. Sokoll, L.J. & Chan, D.W. (1997). Prostate specific antigen. Its discovery and biochemical characteristics. Urologic Clinics North America 24, 253-259.
3. Abrahamsson, P-E., Lilja, H. & Oesterling, J.E. (1997). Molecular forms of serum prostate-specific antigen. Urologic Clinics North America 24, 353-365.
4. Crawford, E.D., DeAntoni, E.P. & Ross, C.A. (1996). The role of prostate-specific antigen in the chemoprevention of prostate cancer. J. Cell. Biochem. 255, 149-155.
5. Montie, J.E. & Meyers, S.E. (1997). Defining the ideal tumor marker for prostate cancer. Urologic Clinics North America 24, 247-252.
6. Christiansen, A., Laurell, C-B. & Lilja, H. (1990). Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors, Eur. J. Biochem. 194, 755-763.
7. Robert, M., Gibbs, B.F., Jacobson, E. & Gagnon, C. (1997). Characterization of prostate-specific antigen proteolytic activity on its major physiologic substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry 36, 3811-3819.
8. Peter, A., Lilja, H. & Malm, J. (1998). Semenogelin I and semenogelin II, the major gel-forming proteins in human semen are substrate for transglutaminase. Eur. J. Biochem. 252, 216-221.
9. Cohen, P., et al. & Rosenfled, R.G. (1992). Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J. Clin. Endocrinol. Metab. 5, 1046-1053.
10. Kanety, H., et al. & Karasik, A. (1993). Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate specific antigen. J. Clin. Endocrinol. Metab. 77, 229-233.
11. Webber, M.M., Waghray, A. & Bello, D. (1995). Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin. Cancer Res. 1, 1089-1-94.
12. Iwamura, M., Hellman, J., Cockett, AT., K., Lilja, H. & Gershagen, S. (1996). Alteration of the hormonal bioactivity of parathyroid-related hormone protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 48, 317-325.
13. Watt, K.W. K., Lee, P-J., M'Timkulu, T., Chan, W-P. & Loor, R. (1986). Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc. Natl Acad. Sci. USA 83, 3166-3170.
14. Schaller, J., Akiyama, K., Tsuda, R., Hara, R., Marti, M. & Rickli, E.E. (1987). Isolation, characterization and amino acid sequence of γ-semenoprotein, a glycoprotein from human seminal plasma. Eur. J. Biochem. 170, 111-120.
15. Clements, J.A. (1994) The human kallikrein gene family: a diversity of expression and function. Mol. Cell. Endocrinol. 99, C1-C6.
16. Akiyama, K., Nakamura, T., Iwanaga, S. & Hara, M. (1987). The chymotrypsin-like activity of human prostate-specific antigen, γ-semenoprotein. FEBS Lett. 225, 168-172.
17. Lilja, H., Abrahamsson P. & Lundwall, A. (1989). Semenogelin, the predominant protein in human semen. J. Biol. Chem. 264, 1894-1900.
18. Denmeade, S.R., Wei, L., Lovgren, J., Malm, J., Lilja, J. & Isaacs, J.T. (1997). Specific and efficient substrates for assaying the proteolytic activity of prostate specific antigen. Cancer Res. 57, 4924-4930.
19. Mathews, D.J. & Wells, J.A. (1993). Substrate phage: selection of protease substrates by monovalent phage display. Science 260, 1113-1117.
20. Smith, M.M., Shi, L. & Navre, M. (1995). Rapid identification of highly active and selective substrates for stromelysin and matrilysin using bacteriophage peptide display libraries. J. Biol. Chem. 270, 6440-6449.
21. Scarborough, P.E., et al., & Dunn, B.M. (1993). Exploration of subsite binding specificity of human cathepsin D through kinetics and rule-based molecular modeling. Protein Sci. 2, 264-272.
22. Kinoshita, A., Urata, H., Bumpus, F.M. & Husain, A. (1991). Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart. J. Biol. Chem. 266, 19192-19197.
23. Ke S-H., Coombs, G.S., Tachias, K., Corey, D.R. & Madison, E.L. (1997). Optimal subsite occupancy and design of a selective inhibitor of Urokinase. J. Biol. Chem. 272, 20456-20462.
24. Ding, L., Coombs, G.S., Strandberg, L., Navre, M., Corey, D.R. & Madison, E.L. (1995). Origins of the specificity of tissue-type plasminogen activator. Proc. Natl Acad. Sci. USA 92, 7627-7631.
25. Villoutreix, B.O., Getzoff, E.D. & Griffin, J.H. (1994). A structural model for the prostate disease marker, human prostate-specific antigen. Protein Sci. 3, 2033-2044.
26. Takayama, T.K., Fujikawa, K. & Davie, E.W. (1997). Characterization of the precursor of prostate-specific antigen. J. Biol. Chem. 272, 21582-21588.
27. Frenette, G., Gervais, Y., Tremblay, R.R. & Dube, J.Y. (1998). Contamination of purified prostate-specific antigen by kallikrein hk2. J. Urology 159, 1375-1378.
28. Bode, W., Chen, Z. & Bartels, W. (1983). Refined 2 A X-ray crystal structure of porcine pancreatic kallikrein A, a specific trypsin-like serine protease. J. Mol. Biol. 164, 237-282.
29. Fiedler, F. (1987). Effects of secondary interactions on the kinetics of peptide and peptide ester hydrolysis by tissue kallikrein and trypsin. Eur. J. Biochem. 163, 303-312
30. Chagas, J.R., et al. & Prado, E.S. (1995). Determinants of the unusual cleavage specificity of lysyl-bradykinin-releasing kallikreins. Biochem. J. 306, 63-69.
31. Fujinaga, M. & James, M.N.G. (1987). Rat submaxillary gland serine protease, Tonin. Solution structure and refinement at 1.8 Å resolution. J. Mol. Biol. 195, 373-396.
32. Grise, C., Boucher, R., Thibault, G. & Genest, J. (1981). Formation of angiotensin II by tonin from partially purified human angiotensinogen. Can. J. Biochem. 59, 250-255.
33. Bridon, D.P. & Dowell, B.L. (1995). Structural comparison of prostate-specific antigen and human glandular kallikrein using molecular modeling. Adult Urol. 45, 801-806.
34. Vihinen, M. (1994). Modeling of prostate specific antigen and human glandular kallikrein structures. Biochem. Biophys. Res. Commun. 204, 1251-1256.
35. Hutschinson, E.G. & Thornton, J.M. (1994). A revised set of potentials for ß-turn formation in proteins. Protein Sci. 3, 2207-2216.
36. Lamba, D., et al. & Bode, W. (1996). The 2.3 A crystal structure of the catalytic domain of recombinant two chain human tissue-type plasminogen activator. J. Mol. Biol. 258, 117-135.
37. Spraggon, G., et al., & Jones, E.Y. (1995). The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure 3, 681-691.
38. Ke, S.-H., Coombs, G.S., Tachias, K., Navre, M., Corey, D.R. & Madison, E.L. (1997). Distinguishing the specificity of closely related proteases. J. Biol. Chem. 272, 16603-16609.
39. Mikolajczyk, S.D., Millar, L.S., Kumar, A. & Saedi, M.S. (1998). Human glandular kallikrein, hK2, shows arginine-restricted specificity and forms complexes with plasma protease inhibitors. Prostate 34, 44-50.
40. Hedstrom, L., Szilagyi, L & Rutter, W.J. (1992). Converting trypsin to chymotrypsin the role of surface loops. Science 255, 1249-1253.
41. Venekei, I., Szilagyi, L., Graf, L. & Rutter, W.J. (1996). Attempts to convert chymotrypsin to trypsin. FEBS Lett. 379, 143-147.
42. Denmeade, S.R., Nagy, A., Gao, J., Lilja, H., Schally, A.V. & Isaacs, J.T. (1998). Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res. 58, 2537-2540.
43. Jameson, G.W., Roberts, D.V., Adams, R.W., Kyle, S.A. & Ellmore, D.T. (1973). Determination of the operational molarity of solutions of bovine α-chymotrypsin, trypsin, thrombin, and factor Xa by spectrofluorometric titration. Biochem. J. 131, 107-117.
44. Taylor, J.R. (1982). An Introduction to Error Analysis: The Study of Uncertainties in Physical Measurements. University Science Books, Mill Valley, CA.
45. Tuffery, P., Etchebest, C., Hazout, C. & Lavery, R. (1991). A new approach to the rapid determination of protein sidechain conformations. J. Biomol. Struct. Dyn. 8, 1267-1289.
46. Brooks, B.R., Bruccoleri, R.E., Olafson, B., D., States, D.J., Swaminathan, S. & Karplus, M. (1983). CHARMM: A program for macromolecular energy, minimization, and molecular graphics. J. Comput. Chem. 4, 187-217.
47. Brünger, A.T. (1992). X-PLOR Manual, Version 3.0. New Haven, Yale University.
48. Powell, M.J.D. (1977). Restart procedures for the conjugate gradient method. Math. Program. 12, 241-254.
49. Brunger, A.T. & Karplus, M. (1988). Polar hydrogen positions in proteins: empirical energy function placement and neutron diffraction comparison Proteins 4, 148-156.
50. Mittl, P.R.E., et al. & Grutter, M.G. (1997). A new structural class of serine protease inhibitors revealed by the structure of the hirustatin-kallikrein complex. Structure 5, 253-264.
51. McRee, D.E. (1992). XtalView: a visual protein crystallographic software system for X11/XView J. Mol. Graph. 10, 44-47.
52. Laskowski, R.A., MacArthur, M.W., Moss, D.S. & Thornton, J.M. (1993). PROCHECK: A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 283-291.
53. Verlet, L. (1967). Computer experiments on classical fluids. I. Thermodynamical properties of Lennard-Jones molecules. Phys. Rev. 159, 89-105.
54. Berendsen, H.J.C., Postma, J.P.M., Van Gunsteren, W.F., DiNola, A. & Haak, J.R. (1984). Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81, 3684-3690.
55. Ryckaert, J.P., Ciccotti, G. & Berendsen, H. (1977). Numerical integration of cartesian equations of motion of a system with constraints. Molecular dynamics of N-alkanes. J. Comput. Phys. 23, 327-341.
56. Schlechter, I. & Berger, A. (1967). On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27, 157-162.
57. McDonald, I.K. & Thornton, J.M. (1994). Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 238, 777-793.
58. Wallace, A.C., Laskowski, R.A. & Thornton, J.M. (1995). LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 8, 127-134.
59. Nicholls, A., Sharp, K.A. & Honig, B. (1991). Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins 11, 281-296.
60. Sitkoff, D., Lockhart, D.J., Sharp, K.A. & Honig, B. (1994). Calculation of the electrostatic effects at the amino terminus of a helix. Biophys. J. 67, 2251-2260.